Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Avadel pharmaceuticals plc save search
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
Published: 2022-04-06 (Crawled : 19:00) - biospace.com/
AVDL | $17.4 -3.28% -3.39% 1.1M
|
Health Technology
|
| O: -0.9%
H: 2.87%
C: 1.06%
trial positive phase 3
Avadel Recognizes World Narcolepsy Day and Announces New Data Presentations from Pivotal Phase 3 REST-ON Trial of FT218 at Upcoming Conference
Published: 2021-09-20 (Crawled : 14:00) - biospace.com/
AVDL | $17.4 -3.28% -3.39% 1.1M
|
Health Technology
|
| O: -1.76%
H: 2.43%
C: 1.02%
presentation narcolepsy phase 3 ft218 trial conference
Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP
Published: 2021-08-16 (Crawled : 12:15) - globenewswire.com
AVDL | $17.4 -3.28% -3.39% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -6.54%
narcolepsy phase 3 ft218 trial
Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit of FT218 in Patients with Narcolepsy at SLEEP 2021
Published: 2021-06-09 (Crawled : 13:00) - globenewswire.com
AVDL | $17.4 -3.28% -3.39% 1.1M
|
Health Technology
|
| O: 1.13%
H: 1.12%
C: -0.37%
phase 3 ft218 trial narcolepsy
Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021
Published: 2021-06-03 (Crawled : 14:00) - globenewswire.com
AVDL | $17.4 -3.28% -3.39% 1.1M
|
Health Technology
|
| O: 1.38%
H: 0.5%
C: -2.1%
phase 3 ft218 trial
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
Published: 2021-04-17 (Crawled : 12:20) - globenewswire.com
AVDL | $17.4 -3.28% -3.39% 1.1M
|
Health Technology
| Email alert
Add to watchlist
phase 3 ft218 trial sodium oxybate
Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study of FT218 at the American Academy of Neurology Annual Meeting 2021
Published: 2021-04-08 (Crawled : 15:00) - biospace.com/
AVDL | $17.4 -3.28% -3.39% 1.1M
|
Health Technology
|
| O: 2.32%
H: 3.63%
C: -0.34%
phase 3 ft218
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.